- CA$15.09m
- CA$24.36m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.
Directors
- Donald Mccaffrey CHM
- Norman Wong CFD
- A. Brad Cann CFO
- Jan Johansson SVP
- Ewelina Kulikowski SVP
- Kenneth Lebioda SVP
- Michael Sweeney SVP
- Norma Biln LED
- Shawn Lu DRC
- Kelly Mcneill IND
- Siu Lun To IND
- Kenneth Zuerblis IND (62)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- February 7th, 2005
- Public Since
- October 12th, 2001
- No. of Employees
- 18
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
Toronto Stock Exchange- Shares in Issue
- 274,295,571
- Address
- 300-4820 Richard Rd SW, CALGARY, T3E 6L1
- Web
- https://www.resverlogix.com/
- Phone
- +1 4032549252
- Auditors
- RSM Canada LLP
Upcoming Events for RVX
Similar to RVX
AEterna Zentaris
Toronto Stock Exchange
Antibe Therapeutics(Pre-Merger)
Toronto Stock Exchange
Appili Therapeutics
Toronto Stock Exchange
Aptose Biosciences
Toronto Stock Exchange
Avicanna
Toronto Stock Exchange
FAQ
What is the Resverlogix share price?
As of Today at 19:18 UTC, shares in Resverlogix are trading at CA$0.06. This share price information is delayed by 15 minutes.
How has the Resverlogix share price performed this year?
Shares in Resverlogix last closed at CA$0.06 and the price had moved by -67.65% over the past 365 days. In terms of relative price strength the Resverlogix share price has underperformed the Toronto Stock Exchange 300 Composite Index by -69.3% over the past year.
What are the analyst and broker recommendations for Resverlogix?
The overall consensus recommendation for Resverlogix is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Resverlogix dividend yield?
Resverlogix does not currently pay a dividend.
Does Resverlogix pay a dividend?
Resverlogix does not currently pay a dividend.
When does Resverlogix next pay dividends?
Resverlogix does not currently pay a dividend.
How do I buy Resverlogix shares?
To buy shares in Resverlogix you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Resverlogix?
As of the previous close price of CA$0.06, shares in Resverlogix had a market capitalisation of CA$15.09m.
Where are Resverlogix shares listed?
Here are the trading details for Resverlogix:
- Country of listing: Canada
- Exchange: TOR
- Ticker Symbol: RVX
What kind of share is Resverlogix?
Based on an overall assessment of its quality, value and momentum Resverlogix is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Resverlogix share price forecast for 2024?
We could not find analyst target price data for this security.
What is the trend in the Resverlogix share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Resverlogix. Over the past six months, its share price has underperformed the Toronto Stock Exchange 300 Composite Index by -31.38%.
As of the last closing price of CA$0.06, shares in Resverlogix were trading -26.08% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Resverlogix PE Ratio?
The Resverlogix PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CA$0.06.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Resverlogix?
Resverlogix's management team is headed by:
- Donald Mccaffrey - CHM
- Norman Wong - CFD
- A. Brad Cann - CFO
- Jan Johansson - SVP
- Ewelina Kulikowski - SVP
- Kenneth Lebioda - SVP
- Michael Sweeney - SVP
- Norma Biln - LED
- Shawn Lu - DRC
- Kelly Mcneill - IND
- Siu Lun To - IND
- Kenneth Zuerblis - IND